SEC filing record
Primary Source · SEC.gov

Satellos Bioscience Inc.

2025 vintageRule 506(b)Filing record

Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.

Latest signalNew Form D filerForm D · 2025-01-03Last filing 2025-01-03

Raised

$25M

Investors

13

Min Invest

None stated

AltStreet Verified Issuer badge

Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.

What this filing shows

·

Every sentence is a value as filed on SEC Form D

Satellos Bioscience Inc. is a Canada (Federal Level) corporation that filed a Form D with the SEC on January 3, 2025 in the Biotechnology industry group. The offering claims Rule 506(b) and covers equity. Satellos Bioscience Inc. reported $25,016,264 sold from 13 investors of a $25,016,264 total offering as of the Form D filed January 3, 2025. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated. The Form D names Haywood Securities (USA) Inc. (CRD 42072), associated with None; Canaccord Genuity LLC (CRD 1020), associated with None as recipients of sales compensation soliciting in CA, CT, MA, NY, OR. Sales commissions are reported as $1,736,980 and finders' fees as $0. Form D allows these to be estimates. The issuer's address of record is 15 Allstate Parkway, Suite 600, Markham, L3R 5B4.

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0001421642
Entity NameSatellos Bioscience Inc.
ExemptionRule 506(b)
What the exemption meansRule 506(b) of Regulation D: securities may be sold to an unlimited number of accredited investors and up to 35 non-accredited investors who meet the rule's sophistication standard, without general solicitation or advertising.
Entity TypeCorporation
Jurisdiction of OrganizationCanada (Federal Level)
Issuer Address15 Allstate Parkway, Suite 600, Markham, L3R 5B4
Phone(647) 660-1780
Former NamesICO THERAPEUTICS INC (until September 10, 2019)
Industry / Fund TypeBiotechnology
Securities TypeEquity
First Sale DateDecember 20, 2024
Filing DateJanuary 3, 2025
Accession Number0001421642-25-000001
Total Offering Amount$25,016,264
Total Amount Sold$25,016,264
Amount Remaining$0
Total Investors13
Non-Accredited InvestorsNone
Minimum Investment$0 (no stated minimum)
Offering DurationOne year or less
Sales Commissions$1,736,980 (to Haywood Securities (USA) Inc. and 1 other)
Finders' Fees$0
Revenue RangeDecline to Disclose
State (Issuer Address)A6
Amendment Count6 filings on record

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

In the Terminal

Filing events

1

latest Jan 3, 2025

Critical / warning

0 / 0

1 watch · 0 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

5

dark, closed

Latest event New filer · Jan 3, 2025

SEC.gov
Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Investor

  • 1 filing event with values and deltas, latest 2025-01-03, and alerts on the next one
  • 5 offering timelines: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

Item 3 changed on the Form D filed 2025-01-03: 5 related persons added and 2 removed against the filing of 2023-05-25; 14 now listed. The names are in the Terminal feed.

Frank Gleeson

Executive Officer, Director, Promoter · Toronto, A6

Michael Rudnicki

Executive Officer · Toronto, A6

Elizabeth Williams

Executive Officer · Toronto, A6

Geoff MacKay

Director · Toronto, A6

Adam Mostafa

Director · Toronto, A6

Brian Bloom

Director · Toronto, A6

William McVicar

Director · Toronto, A6

Bill Jarosz

Director · Toronto, A6

Rima Al-awar

Director · Toronto, A6

Michael Robert Cross

Executive Officer · Toronto, A6

Philip D. Lambert

Executive Officer · Toronto, A6

Courtney D. Wells

Executive Officer · Toronto, A6

Franklin D. Berger

Director · Toronto, A6

Stephanie D. Brown

Director · Toronto, A6

Placement Agents and Sales Compensation (Form D)

Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.

Haywood Securities (USA) Inc.CRD 42072 on BrokerCheck

Associated broker-dealer: None · Vancouver, A1 · Soliciting in CA, CT, MA, NY, OR

Canaccord Genuity LLCCRD 1020 on BrokerCheck

Associated broker-dealer: None · New York, NY · Soliciting in NY

Questions About Satellos Bioscience Inc.

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is Satellos Bioscience Inc.?

Satellos Bioscience Inc. is a Canada (Federal Level) corporation that filed a Form D with the SEC on January 3, 2025 in the Biotechnology industry group. The filing claims Rule 506(b) for an offering of equity.

Is Satellos Bioscience Inc. legit?

AltStreet does not rate legitimacy; it reports the public record. Satellos Bioscience Inc. filed a Form D with the SEC on January 3, 2025 claiming Rule 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $25,016,264 sold to 13 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is Satellos Bioscience Inc. registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Satellos Bioscience Inc. claimed Rule 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has Satellos Bioscience Inc. raised?

Satellos Bioscience Inc. reported $25,016,264 sold from 13 investors of a $25,016,264 total offering as of the Form D filed January 3, 2025.

Who can invest in Satellos Bioscience Inc.?

The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.

What is the minimum investment in Satellos Bioscience Inc.?

The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.

Who is selling Satellos Bioscience Inc. and how are they paid?

The Form D names Haywood Securities (USA) Inc. (CRD 42072), associated with None; Canaccord Genuity LLC (CRD 1020), associated with None as recipients of sales compensation soliciting in CA, CT, MA, NY, OR. Sales commissions are reported as $1,736,980 and finders' fees as $0. Form D allows these to be estimates.

Who is behind Satellos Bioscience Inc.?

The Form D lists 14 related persons: Frank Gleeson, executive officer, director, promoter; Michael Rudnicki, executive officer; Elizabeth Williams, executive officer; Geoff MacKay, director; Adam Mostafa, director; Brian Bloom, director; William McVicar, director; Bill Jarosz, director, and 6 more. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is Satellos Bioscience Inc. located?

The issuer's address on its SEC filings is 15 Allstate Parkway, Suite 600, Markham, L3R 5B4. Its phone number of record is 647-660-1780. It is organized under the laws of Canada (Federal Level).

How long is the Satellos Bioscience Inc. offering open?

The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open, and no amendment is on record yet.

What is Satellos Bioscience Inc.'s revenue?

The issuer declined to disclose its revenue range on the Form D, which the form permits.

AltStreet Verified Issuer badge

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.